TY - JOUR
T1 - Outcomes following less-invasive-surfactant-administration in the delivery-room
AU - Arattu Thodika, Fahad M.S.
AU - Ambulkar, Hemant
AU - Williams, Emma
AU - Bhat, Ravindra
AU - Dassios, Theodore
AU - Greenough, Anne
N1 - Funding Information:
The research was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. Chiesi funded this study, but were not involved in its design, performance or analysis. EEW was supported by the Charles Wolfson Charitable Trust and additionally by SLE.
Publisher Copyright:
© 2022 Elsevier B.V.
PY - 2022/4
Y1 - 2022/4
N2 - Background: Less invasive surfactant administration (LISA) on the neonatal unit reduces the need for mechanical ventilation and bronchopulmonary dysplasia (BPD). Aims: To assess the immediate and longer-term efficacy of LISA to prematurely born infants in the delivery-room. Study design: A case control study with inborn historical controls matched for gestational age, birthweight and gender to each LISA infant. Subjects: Infants born between 26+0 weeks and 34+6 weeks of gestational age. Outcome measures: Respiratory function monitoring before and after LISA and need for mechanical ventilation within 72 h of birth. Results: Ninety-nine infants, median gestational age of 32+4(range:27+0–34+6) weeks, were prospectively recruited. The respiratory rate and inspired oxygen (FiO2) decreased two minutes after LISA and there was a reduction in the FiO2 requirement at two hours post birth. Compared to historical controls, LISA administration was associated with a reduction in the need for mechanical ventilation within 72 h after birth (20.2% versus 56.6% p < 0.001) the incidence of moderate to severe BPD (8.2% versus 20.2%, p = 0.02) and the median costs of neonatal intensive care stay (£1218 versus £2436, p = 0.03) and total neonatal unit stay (£12,888 versus £17,240, p = 0.04). A high FiO2 in the delivery-room pre-LISA (median 0.75 versus 0.60, p = 0.02) was associated with LISA failure, that is mechanical ventilation within 72 h of birth. Conclusions: LISA to prematurely born infants in the delivery-room was associated with reductions in the need for mechanical ventilation and costs of care, but was less successful in those with initial, more severe respiratory disease.
AB - Background: Less invasive surfactant administration (LISA) on the neonatal unit reduces the need for mechanical ventilation and bronchopulmonary dysplasia (BPD). Aims: To assess the immediate and longer-term efficacy of LISA to prematurely born infants in the delivery-room. Study design: A case control study with inborn historical controls matched for gestational age, birthweight and gender to each LISA infant. Subjects: Infants born between 26+0 weeks and 34+6 weeks of gestational age. Outcome measures: Respiratory function monitoring before and after LISA and need for mechanical ventilation within 72 h of birth. Results: Ninety-nine infants, median gestational age of 32+4(range:27+0–34+6) weeks, were prospectively recruited. The respiratory rate and inspired oxygen (FiO2) decreased two minutes after LISA and there was a reduction in the FiO2 requirement at two hours post birth. Compared to historical controls, LISA administration was associated with a reduction in the need for mechanical ventilation within 72 h after birth (20.2% versus 56.6% p < 0.001) the incidence of moderate to severe BPD (8.2% versus 20.2%, p = 0.02) and the median costs of neonatal intensive care stay (£1218 versus £2436, p = 0.03) and total neonatal unit stay (£12,888 versus £17,240, p = 0.04). A high FiO2 in the delivery-room pre-LISA (median 0.75 versus 0.60, p = 0.02) was associated with LISA failure, that is mechanical ventilation within 72 h of birth. Conclusions: LISA to prematurely born infants in the delivery-room was associated with reductions in the need for mechanical ventilation and costs of care, but was less successful in those with initial, more severe respiratory disease.
KW - Healthcare cost
KW - LISA
KW - LISA failure
KW - Respiratory function monitor
UR - http://www.scopus.com/inward/record.url?scp=85125453872&partnerID=8YFLogxK
U2 - 10.1016/j.earlhumdev.2022.105562
DO - 10.1016/j.earlhumdev.2022.105562
M3 - Article
AN - SCOPUS:85125453872
SN - 0378-3782
VL - 167
JO - Early Human Development
JF - Early Human Development
M1 - 105562
ER -